Novartis Faces $291 Million Lawsuit over Alleged Misappropriation of Hedge Fund Strategy
In a legal move that could significantly impact the biotech industry, Novartis is facing a $291 million lawsuit from a hedge fund. The hedge fund alleges that Novartis, alongside a former investment executive and his business partner, conspired to misappropriate an “innovative hedge fund strategy.” This accusation comes in the wake of a failed investment…